Defining a new threshold for PSA outcomes in untreated prostate cancer.

被引：0
|
作者：
Beekman, KW [1 ]
Wilton, A [1 ]
Heller, G [1 ]
Bianco, FJ [1 ]
Lilja, H [1 ]
Slovin, S [1 ]
Scardino, PT [1 ]
Scher, HI [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4587
引用
收藏
页码：403S / 403S
页数：1
相关论文
共 50 条
  • [41] Simulation optimization of PSA-threshold based prostate cancer screening policies
    Daniel J. Underwood
    Jingyu Zhang
    Brian T. Denton
    Nilay D. Shah
    Brant A. Inman
    Health Care Management Science, 2012, 15 : 293 - 309
  • [42] PSA and prostate cancer screening: The challenge of the new millennium
    Bjartell, Anders
    EUROPEAN UROLOGY, 2007, 52 (05) : 1284 - 1286
  • [43] Hospital variation in outcomes after surgery for prostate cancer.
    Hassett, Michael J.
    Mossanen, Matthew
    Weng, Shicheng
    Cronin, Angel M.
    Uno, Hajime
    McNiff, Kristen K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30)
  • [44] Health outcomes in older men with localized prostate cancer.
    Hoffman, RM
    Barry, MJ
    Collins, MM
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2005, 20 : 55 - 56
  • [45] Inpatient outcomes of pathological fractures in metastatic prostate cancer.
    Ahuja, Kriti
    Lingamaneni, Prasanth
    Laswi, Hisham
    Kumi, Dennis Danso
    Chhabra, Navika
    Darweesh, Omnia
    Batra, Kunnal
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Relationship between undetectable PSA nadir and outcomes for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in IRONMAN, the International Registry for Men with Advanced Prostate Cancer.
    McManus, Hannah Dzimitrowicz
    Howard, Lauren
    Crowell, Kerri-Anne
    Hyslop, Terry
    Autio, Karen A.
    Rathkopf, Dana
    Dreicer, Robert
    Chi, Kim N.
    Ong, Michael
    Mateo, Joaquin
    Enting, Deborah
    Esteban, Emilio
    Khoo, Vincent
    Mcmannis, Amanda
    Green, Rebecca
    Pileggi, Shannon
    Vinson, Jake
    Kantoff, Philip W.
    Mucci, Lorelei A.
    George, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [47] Defining the appropriate radiation dose for pretreatment PSA ≤ 10 ng/mL prostate cancer
    Pinover, WH
    Hanlon, AL
    Horwiltz, EM
    Hanks, GE
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (03): : 649 - 654
  • [48] Evaluation of a predefined AS threshold in a large cohort of men with localized prostate cancer.
    Canter, Daniel
    Reid, Julia E.
    Latsis, Maria
    Variano, Margaret
    Halat, Shams
    Gurtner, Kristen E.
    Brawer, Michael K.
    Stone, Steven
    Bardot, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [49] Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer
    Stephenson, AJ
    Aprikian, AG
    Souhami, L
    Behlouli, H
    Jacobson, AI
    Bégin, LR
    Tanguay, S
    UROLOGY, 2002, 59 (05) : 652 - 656
  • [50] Synthesis and biological evaluation of novel PSA-specific peptide prodrugs for prostate cancer.
    Mhaka, AM
    Yao, W
    Denmeade, SR
    Isaacs, JT
    Khan, S
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3675S - 3675S
12345